We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · June 30, 2021

EAN 2021: Real-World Follow-Up Confirms Favorable Risk-Benefit of Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis

Relapse rates diminished and patient-reported outcomes improved or remained stable

PracticeUpdate Editorial Team


Further Reading